
Neurology News Network for the week ending November 14th, 2026. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending November 14th, 2026. [WATCH TIME: 6 minutes]

Dr. Vernon explains that TAZ gene mutations disrupt cardiolipin remodeling in the inner mitochondrial membrane, leading to buildup of immature monolysocardiolipin and impaired ATP synthesis that underlies all major clinical features, while Dr. Husain frames energy demand across life stages (feeding in infancy, recess activity in school age, declining exercise tolerance in adulthood) and the panel discusses the dual burden of cardiac and skeletal muscle dysfunction that makes fatigue difficult to attribute to either.

Dr. Husain outlines the disease course from infancy (cardiomegaly, dilated ventricles, feeding failure, and risk of cardiogenic shock) through a “honeymoon period” of ages 5-25 marked by ongoing neutropenia, growth delay, and frequent specialist visits, to long-term mortality driven mainly by heart failure (~50%), sepsis (~20%), and arrhythmia (~20%), while Dr. Vernon notes that later-diagnosed patients often present with neutropenia but no obvious early cardiomyopathy, pointing to underdiagnosis of milder phenotypes.

As treatment options for generalized myasthenia gravis continue to expand, Ali Habib, MD, explores how clinicians can refine therapeutic decisions to prioritize sustained disease control, patient function, and quality of life.

Dual BAFF and APRIL inhibition offers a distinct strategy for modifying B-cell and plasma-cell survival while potentially occupying a middle ground in treatment onset. Supported by Vor Bio Medical Affairs.

Following the release of phase 3 NIMBLE findings, Ali Habib, MD, examines the clinical significance of cemdisiran's MG-ADL results alongside key safety and tolerability considerations.

CAR-T approaches may offer a new level of immune targeting in MG, but durability, logistics, safety, and retreatment remain central questions. Supported by Vor Bio Medical Affairs.

The professor of medicine at McMaster University discussed the significance of asundexian’s approval, how a stroke-specific dose-finding approach shaped its development, and what OCEANIC-STROKE showed. [WATCH TIME: 6 minutes]

The professor of medicine at McMaster University discussed the FDA approval of asundexian, why secondary prevention of noncardioembolic stroke has lagged behind, and the phase 3 OCEANIC-STROKE trial. [WATCH TIME: 5 minutes]

Partial response, wearing off, and fluctuating control can signal that an FcRn strategy needs to be reconsidered. Emerging switching experience suggests that inadequate response to one therapy may not represent failure of an entire class.

Immune processes that form lesions and erode reserve appear to reinforce each other. Genetic, environmental, and host factors add heterogeneity, which strengthens the case for individualized assessment.

There is no single targeted therapy pathway for every patient with MG. Antibody status, disease history, comorbidities, and practical treatment considerations all shape mechanism selection.

Irreversible tissue injury starts at disease onset and may stay silent for years. Relapsing and progressive biology differ in emphasis, but the panel sees them as overlapping rather than separate diseases.

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton discussed a recent analysis of the PROSPECT trial of using transcutaneous afferent patterned stimulation in essential tremor. [WATCH TIME: 5 minutes]

The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discusses how NMAC will identify its 2027 priorities through community feedback on care access, research, and disability rights. [WATCH TIME: 3 minutes]

The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discusses NMAC's transition toward year-round collaboration and its role in advancing neuromuscular research, treatment access, and care. [WATCH TIME: 3 minutes]

A normal lactate and nonspecific histopathology do not exclude TK2D in adults. Retrieving stored muscle tissue for mitochondrial DNA studies can reach a diagnosis when initial biopsy analysis falls short.

Approval shifts access from research programs to insurance review and specialty pharmacy. Honest counseling about realistic goals, and about the value of early treatment, helps families engage with therapy.

Neurology News Network for the week ending November 7th, 2026. [WATCH TIME: 5 minutes]

Episode 5 of Gray Areas features a conversation with Tobia Zanotto, PhD, examining whether frailty in multiple sclerosis is a preventable condition, what the current evidence on rehabilitation interventions shows, and where research needs to go next.

Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with miv-cel in patients with stiff person syndrome.

B-cell depletion can reduce pathogenic immune activity, but persistent plasma-cell reservoirs and long-term immune effects remain important therapeutic challenges. Supported by Vor Bio Medical Affairs.

CD19 and CD20 targeting reach different points along the B-cell lineage, creating distinct clinical questions about efficacy, onset, and patient selection in MG. Supported by Vor Bio Medical Affairs.

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed open-label extension data from the phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 6 minutes]

The decision to escalate MG therapy is driven by more than numerical disease severity. Persistent functional impairment may justify earlier targeted treatment even when symptoms appear clinically modest.

Treatment success in MG depends on what matters to the individual patient. Shared decision-making may also help identify patients who warrant earlier targeted treatment.

The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's 2026 conference, its new interdisciplinary consensus guidelines, and the next steps for stuttering care. [WATCH TIME: 5 minutes]

The director of the Pediatric Neuromuscular Program at UCSF Benioff Children’s Hospital San Francisco discussed 2-year findings from the phase 2/3 VIBRANCE-MG study of nipocalimab in adolescents with generalized MG. [WATCH TIME: 6 minutes]

Dr. Muley highlights patient-reported experience from MINT: the once-every-six-month maintenance regimen (after initial loading doses) was well-received, giving patients extended windows free from treatment considerations.

Dr. Muley frames two use cases: (1) Early use (<1 year disease duration) to intercept long-lived plasma cell formation and potentially reduce steroid/immunosuppressant reliance; (2) Later use in patients who have failed steroids, conventional ISTs, or downstream therapies (FcRn inhibitors, complement inhibitors).